{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-000069","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2022-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.024382+00:00","generated_at":"2026-06-27T21:29:51.094216+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immix Biopharma gets FDA Rare Pediatric Disease designation for IMX-110 in rhabdomyosarcoma","bullets":["FDA granted Rare Pediatric Disease designation for IMX-110 to treat rhabdomyosarcoma, a life-threatening pediatric cancer.","If approved, Immix may receive a Priority Review Voucher (PRV), historically sold for $67M to $350M, transferable to other companies.","IMX-110 is currently in a Phase 1b/2a clinical trial and also has orphan drug designation for soft tissue sarcoma.","Company believes IMX-110 targets all three components of the tumor micro-environment via its SMARxT platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-000069","json":"https://secwatch.observer/filing/0001493152-22-000069.json","markdown":"https://secwatch.observer/filing/0001493152-22-000069.md","text":"https://secwatch.observer/filing/0001493152-22-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315222000069/0001493152-22-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315222000069/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T21:29:51.094216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}